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Background: A comparison of the longitudinal progression of lung disease in cystic fibrosis patients identified through newborn screening (NBS)
in cohorts located in two different countries has never been performed and was the primary objective of this study.
Methods: The study included 56 patients in Brittany diagnosed through NBS between 1989 and 1994 and 69 similar patients in Wisconsin
between 1985 and 1994. The onset and progression of lung disease was radiographically quantified using the Wisconsin Chest X-ray (WCXR)
scoring system. A single pediatric pulmonologist blinded to all identifiers scored the films.
Results: Generalized estimating equation analyses adjusted for age, genotype, sex, pancreatic insufficiency, and meconium ileus showed worse
WCXR scores in Brittany patients compared to Wisconsin patients (average score difference=4.48; pb0.001). Percent predicted FEV1 was also
worse among Brittany patients (pb0.001).
Conclusions: The finding of milder radiographically-quantified lung disease using the WCXR scoring system, as well as better FEV1 values, may
be explained by variations in nutrition, environmental exposures, or healthcare delivery.
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The regions of Wisconsin, United States, and Brittany,
France have a very long history of newborn screening (NBS) for
cystic fibrosis (CF), with screening having begun in 1985 in⁎ Corresponding author. 610 Walnut Street, 785 WARF, Madison, WI 53726-
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1 Brittany CF centre directors: Michel Dagorne (Saint Brieuc), Valérie
Moisan-Petit (Vannes), Marie-Reine Munck (Brest), Gilles Rault (Roscoff),
Michel Roussey (Rennes), Philippe Vic (Quimper), Philippe Vigneron
(Lorient).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.10.004Wisconsin and in 1989 in Brittany [1–3]. Each region also has
extensive experience with longitudinal epidemiologic studies
[3–9], and the two regions have collaborated on a genotype-
pulmonary phenotype project [10]. Although early diagnosis
through NBS leads to uniformly better nutritional status [11] in
all regions that have studied that outcome, there has been very
little comparative evaluation of lung disease onset and
progression after screening. To the best of our knowledge, a
study comparing longitudinal pulmonary outcomes of children
from regions of different countries has not yet been performed.
Consequently, the regions of Wisconsin and Brittany afforded
us an opportunity for such a study. Indeed, the comparability ofd by Elsevier B.V. All rights reserved.
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longitudinal progression of pulmonary disease, the major
source of morbidity and mortality in patients with CF [11],
among patients from two regions of different countries.
Longitudinal quantitative chest radiography has been shown
to be a sensitive method of detecting worsening pulmonary
disease in children with CF, and correlates well with clinical
variables [5,12,13]. It is especially useful when study patients
are too young to perform lung function tests, such as spirometry
[13]. Specifically, the Wisconsin Chest X-ray scoring system
(WCXR) is more sensitive for detecting mild pulmonary disease
in CF than the more commonly used Brasfield Chest X-ray
scoring system (BCXR) [14,15]. We chose to use the WCXR in
our study of longitudinal pulmonary outcomes.
Studies of CF that compare patients in different countries are
rare. Our group performed a cross-sectional study of nutritional
outcomes comparing U.S. and Canadian CF patients by using
data from the national registries in each country [16], which
showed slightly better growth indices among Canadian patients
compared to U.S. patients. Another study was an international
comparison of median age at death from cystic fibrosis [17]. The
authors concluded that among the 10 industrialized countries
studied, median age at death was highest in the United States.
However, Francewas not among the 10 countries because the data
for France were in longer intervals than the other countries.
Notably absent from the literature are longitudinal studies
comparing CF patients who were found through newborn
screening and closely followed over multiple years.
Because of the existence of specialized CF centres in both
Brittany and Wisconsin, where the care is standardized [9,18],
and because of the similarity of the newborn screened
populations, we hypothesized that the progression of lung
disease using the WCXR scoring system would not differ
significantly between CF patients in Brittany and Wisconsin.
2. Methods
The study included 56 CF patients who underwent NBS in
Brittany between January 1989 and July 2000, and 69
Wisconsin patients who underwent NBS between April 1985
and July 1994. Both regions have complete NBS programmes
covering their populations. In Brittany, NBS was carried out
with immunoreactive trypsinogen (IRT) tests until September
1991, at which time IRT/DNA testing was instituted. Wisconsin
also changed its NBS algorithm to IRT/DNA in July 1991
[4,19], which has a sensitivity of about 95%. All screened
patients had a confirmatory sweat test around 4–6 weeks of age,
after which they began treatment for CF, since at the time of the
study it was believed that younger infants would not be able to
produce a sufficient volume of sweat for the test [20]. All
patients were followed at specialized CF centres in Wisconsin
(Madison and Milwaukee) or Brittany (Roscoff, Rennes, Brest,
Vannes, Lorient, Quimper, and St. Brieuc). Clinical manage-
ment was similar between the two groups and included high
energy intake, supplementation with pancreatic enzymes and
fat-soluble vitamins, daily respiratory therapy, and treatment
with antibiotics depending on respiratory symptoms andcultures; none of the centres used prophylactic anti-staph
antibiotics. The staffing of the centres was also similar.
Lung disease was quantified using the WCXR scoring system
described previously [14,15] using original postero-anterior and
lateral films. In Brittany, chest X-ray films were collected at
diagnosis and then at ages 1, 2, 3, 4, 5, 6, 8, and 10–12 nearest the
patient's birthday when available. In Wisconsin, films were
collected at the time of enrollment in the newborn screening study
and then at ages 2, 4, 5, 6, 7, 8, 9, 10, 11, and 12 nearest the
patient's birthday. All films were scored by a single pediatric
pulmonologist (PMF) blinded to all identifiers, including patient,
centre, and country; this was accomplished by applying tape over
all films and covering all identifiers. Wisconsin films were scored
in Madison, while Brittany films were scored in Roscoff, France
using a similar room, multi-panel viewing box, and a bright light.
However, representative Wisconsin chest radiographs were
deidentified and brought to Brittany for the scoring sessions
there and then repeatedly mixed with those of French patients.
The reproducibility of scoring was assessed by interspersing a
subset of films that were scored previously from Wisconsin
(n=10) and from Brittany patients (n=31). We have used this
quality control strategy successfully on many occasions in the
past [5,7,8,14] and prefer it to other methods.
Data were collected on baseline risk factors, including
sex, genotype, meconium ileus, pancreatic insufficiency, age at
diagnosis, and weight and height at various ages. Genotype
was determined as described elsewhere [10] and controlled for
using three categories: 1) F508del homozygotes; 2) F508del
compound heterozygotes; and 3) those with two other mutations
(only 6% of the two cohorts). The molecular techniques used
resulted in a very high CF mutation detection rate (99% in
Brittany and N95% in Wisconsin) [21,22]. Weight-for-age and
height-for-age percentiles were compared separately for
male and female patients at ages 6 and 10 using French growth
chart data for Brittany patients and U.S. growth chart data for
Wisconsin patients. Data were also collected on time-dependent
risk factors, including yearly FEV1 values and days of hospi-
talization per year. Percent predicted FEV1 values based on a
patient's age and height were calculated using international
standards [23].
2.1. Statistical methods
SAS version 9.10 (SAS Institute, Cary, NC) was used for all
statistical analyses. Generalized estimating equation (GEE)
models were used to compare longitudinal progression of
WCXR scores and longitudinal progression of percent predicted
FEV1 in the two cohorts. Another GEE model was constructed
comparing longitudinal progression of WCXR scores among
F508del homozygotes in the two populations. Additionally, a
GEE model was constructed comparing WCXR scores among
the larger CF centres (Madison, Milwaukee, Rennes, Roscoff,
Brest, and St. Brieuc). Because of skewing in the data for
number of days hospitalized between regular visits to CF
centres, with many patients having no hospital days between
visits, a GEE model comparing longitudinal odds of being
hospitalized between visits was performed. Analyses were
Table 2
GEE analysis of the longitudinal WCXR scores for age b12.5 years.
Factors Class Difference±SE
(p-value)
Age 1.33±0.09 (pb0.001) per year
Region Brittany 4.48±0.99 (pb0.001) vs Wisconsin
Sex Male
Female 1.37±0.96 (p=0.15) vs male
Genotype F508del/F508del 0.89±3.75 (p=0.81) vs other/other
F508del/other −1.27±3.74 (p=0.73) vs other/other
Other/other
Pancreatic status Pancreatic sufficiency
Pancreatic insufficiency − .41±2.56 (p=0.87) vs PS
Meconium ileus No
Yes −1.39±1.37 (p=0.31) vs no
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insufficiency, and presence of meconium ileus.
3. Results
Characteristics of study patients are displayed in Table 1.
There were no significant differences between Wisconsin and
Brittany patients with respect to sex, genotype, presence of
pancreatic insufficiency, presence of meconium ileus, or age at
diagnosis. Using T-tests, male patients in Brittany did not differ
significantly (pN .05) in weight or height from male patients in
Wisconsin, although the country-specific percentile for the mean
value of weight was somewhat lower for Wisconsin patients at
age 10 (39th percentile) compared to Brittany patients at age 10
(49th percentile). Again using T-tests, female patients from
Brittany were significantly shorter and weighed less than
Wisconsin patients at both ages 6 and 10, and the country-
specific percentiles for the mean values of weight and height were
also lower for female Brittany patients thanWisconsin patients at
ages 6 and 10. However, the lowest percentile for female patients
in Brittany was for weight at age 10, which was the 37th
percentile, showing that the average female Brittany patient in the
study was not malnourished.
A total of 1003 chest radiographs were scored, an average of
8.88 radiographs per patient. Inclusion of 10 Wisconsin films
that had already been scored in Wisconsin to the panel of films
of Brittany patients yielded similar WCXR scores for the same
film scored at each location (p=0.82). Likewise, inclusion of 31
Brittany films that had already been scored in Brittany to the
panel of films yet to be scored resulted in similar WCXR scores
for the same film scored two separate times (p=0.13).
All GEE models were restricted to age b12.5, since no chest
radiographs of patients older than 12 years of age were collected
in Brittany. Longitudinal analysis of the progression of CXR
scores is shown in Table 2. WCXR scores analyzed by regionTable 1
Characteristics of study patients born up to 6/30/1994 (all screened with sweat test
Characteristics Class W
Age in weeks at diagnosis, mean±SD (median) 12
Genotype Female 28
F508del/F508del 39
F508del/other 28
Other/other 2
Pancreatic status Pancreatic sufficiency 7
Pancreatic insufficiency 61
Meconium ileus No 56
Yes 13
Age 6 Height in cm (males) 11
Weight in kg (males) 20
Height in cm (females) 11
Weight in kg (females) 20
Age 10 Height in cm (males) 13
Weight in kg (males) 31
Height in cm (females) 13
Weight in kg (females) 33
a Data are expressed as N (%) unless otherwise noted.
b SD.
c Percentiles are of the mean.were significantly worse in Brittany compared to Wisconsin
(pb0.001), with an average difference in score of 4.48. As
expected, WCXR scores worsened with increasing age
(pb0.001), with an average increase in WCXR score of 1.33
per year. Baseline risk factors including sex, genotype, the
presence of pancreatic insufficiency, and the presence of
meconium ileus were not significantly associated with WCXR
scores. On the other hand, when either weight data or
hospitalizations were added into the GEE model as potential
explanatory variables, the effect of regional variations could not
be detected. Therefore, the child's weight (or hospitalization
history) and region may have confounding effects; in other words
the effect of region (Brittany orWisconsin) onWCXR scoresmay
be partly explained by weight and/or hospitalizations.
Longitudinal analysis of the progression ofCXR scores among
F508del homozygotes was performed separately. This analysis
was intended to compare the progression of lung disease among
subgroups of similar classic CF patients with a common genotype
in Brittany and Wisconsin. Similar results were found with thischloride level ≥60) from diagnosis up to age 12.5 years.
isconsin N (%) (n=69) Brittany N (%) a (n=56) p-value
±34 (6.86) 22±74 (4.43) 0.37
(41) 30 (54) 0.15
(57) 33 (59)
(41) 18 (32)
(3) 5 (9) 0.27
(10) 6 (11)
(90) 48 (89) 0.88
(81) 51 (91)
(19) 5 (9) 0.12
5.40±5.58 b (48th percentile) c 114.17±5.56 (54th percentile) 0.37
.88±2.44 (52nd percentile) 20.46±2.54 (58th percentile) 0.26
5.57±5.51 (54th percentile) 111.96±5.32 (41st percentile) 0.031
.89±3.40 (57th percentile) 19.02±2.13 (41st percentile) 0.037
6.98±7.56 (39th percentile) 134.85±5.64 (49th percentile) 0.28
.71±5.55 (47th percentile) 29.54±5.05 (48th percentile) 0.16
8.38±7.95 (51st percentile) 134.12±5.13 (40th percentile) 0.045
.97±8.64 (56th percentile) 29.49±3.50 (37th percentile) 0.034
Table 4
Percent predicted FEV1. a
Age in years Brittany Wisconsin p-value
Mean±SD Mean±SD
6 83.64±19.02 97.76±17.69 0.003
7 83.65±20.12 96.92±14.64 b0.001
8 86.73±17.30 97.25±17.75 0.004
9 83.58±22.56 93.98±18.74 0.016
10 85.55±21.24 97.37±14.38 0.002
11 83.02±19.35 93.26±18.12 0.02
a Pearson correlation coefficients were calculated for the correlation between
percent predicted FEV1 and WCXR scores; scored chest X-rays of patients who
had a percent predicted FEV1 value within 1 year of the X-ray were used for this
analysis.
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More specifically, WCXR scores were significantly worse in
Brittany compared to Wisconsin (pb0.0001), with an average
difference in score of 5.95. As expected, WCXR scores worsened
with increasing age (pb0.0001), with an average increase in
WCXR score of 1.55 per year.
Longitudinal analysis of percent predicted FEV1 is shown in
Table 3; the results are similar to those found with the WCXR
scores. Brittany patients had worse percent predicted FEV1
values over time compared to Wisconsin patients (pb0.001);
the average difference between the two populations was
11.56%. The correlation coefficient between percent predicted
FEV1 and WCXR scores using 160 data points was −0.33
(pb0.0001). As expected, percent predicted FEV1 was worse
with increasing age (p=0.05); the average difference per year
was 0.85%. Patients with pancreatic insufficiency also had
worse percent predicted FEV1 over time (p=0.05); the average
difference between patients with pancreatic insufficiency and
pancreatic sufficiency was 9.20%. Additionally, patients with
meconium ileus had worse percent predicted FEV1 over time
(p=0.043); the average difference between patients with
meconium ileus and those without meconium ileus was 9.35%.
Table 4 shows percent predicted FEV1 values for Brittany
and Wisconsin patients between ages 6 and 11. Percent
predicted FEV1 is significantly lower for Brittany patients
than for Wisconsin patients at all ages shown in the table.
GEE analysis of the longitudinal progression of WCXR
scores by CF centre shows no significant differences among the
4 largest CF centres in Brittany. The other centres followed too
few patients to be included in this analysis. When compared to
the average WCXR score in Rennes, the difference in average
score was −1.08 in Roscoff (p=0.47), 2.04 in St. Brieuc
(p=0.26), and −4.70 in Vannes (p=0.44). There were
significant differences between the average WCXR score in
Rennes and the two Wisconsin CF centres, showing that the
patients followed at the Wisconsin CF centres had significantly
better WCXR scores than those followed in Rennes. When
compared to the average WCXR in Rennes, the difference in
average score was −4.70 in Madison (p=0.0006) and −4.00 in
Milwaukee (p=0.0019).Table 3
GEE analysis of the longitudinal % predicted FEV1 for age b12.5 years.
Factors Class Difference±SE (p-value) in %
predicted FEV1
Age −0.85±0.44 (p=0.05) per year
Region Brittany −11.56±3.07 (pb0.001) vs Wisconsin
Sex Male
Female −1.22±3.18 (p=0.70) vs male
Genotype F508del/F508del −5.26±8.49 (p=0.54) vs other/other
F508del/other −3.74±8.80 (p=0.67) vs other/other
Other/other
Pancreatic
status
Pancreatic sufficiency
Pancreatic insufficiency −9.20±4.70 (p=0.05) vs PS
Meconium
ileus
No
Yes −9.35±4.62 (p=0.043) vs noLongitudinal analysis of the odds of hospitalization showed
that Brittany patients were more likely than Wisconsin patients
to be hospitalized between regular CF visits (pb0.0001;
OR=18.82). Both a younger age and the presence of meconium
ileus were associated with an increased likelihood of hospital-
ization between regular CF visits (for increasing age: OR=0.95,
p=0.016; for meconium ileus: OR=2.08, p=0.021). Sex,
genotype, and presence of pancreatic insufficiency were not
associated with the odds of hospitalization.
Fig. 1 displays the mean WCXR scores at each age for
Brittany and Wisconsin patients. In both populations, WCXR
scores worsen with increasing age. WCXR scores are somewhat
similar among the two populations until the age of 2, at which
time Brittany patients show a more rapid worsening of scores.
This increased rate of worsening occurs until age 6, at which
time there is a stable worsening of scores in both populations.
Fig. 2 displays the mean peribronchial thickening and
bronchiectasis subcomponents of the WCXR scores at each age
for Brittany and Wisconsin patients. In both populations, the
peribronchial thickening score worsens with age, but among
Brittany patients, there is a faster rate of development of
peribronchial thickening compared to Wisconsin patientsFig. 1. Longitudinal WCXR scores in Brittany and Wisconsin CF patients
identified through newborn screening. The scale of the WCXR scoring system is
from 0 to 100, with higher scores denoting worsening pulmonary disease. The
graph of WCXR scores clearly shows worse scores for Brittany patients compared
to Wisconsin patients, particularly between ages 2 and 6.
Fig. 2. Longitudinal WCXR peribronchial thickening scores (upper graph) and
bronchiectasis scores (lower graph) in Brittany and Wisconsin CF patients
identified through newborn screening. A higher peribronchial thickening score
correlates with increased peribronchial thickening, and a higher bronchiectasis
score correlates with increased bronchiectasis. Brittany patients have more
peribronchial thickening than Wisconsin patients with difference ±SE, 0.74±
0.29, p=0.01 by GEE. Brittany patients have more bronchiectasis than
Wisconsin patients with difference±SE, 2.94±0.49, pb0.001 by GEE.
48 A.C. Walsh et al. / Journal of Cystic Fibrosis 9 (2010) 44–50beginning at age 5. In both populations, the bronchiectasis score
worsens with increasing age. However, there is a faster rate of
development of bronchiectasis among the Brittany patients
compared to the Wisconsin patients at all ages. The rapid rate of
increase in bronchiectasis scores is most pronounced in patients
under the age of 5.
To compare these CXR scores with results published by
others, particularly the innovative strategy of McCormick et al.
[12] using centile charts, we transformed our WCXR scores into
centile scores and then compared the two groups. For all the
patients and all the periods up to age 12.5 years, the minimum is 0
and the maximum 52.95 in WCXR scores, and the mean WCXR
score 13.81 for Brittany and 11.52 for Wisconsin patients. Using
the minimum of 0 as the 0th centile and the maximum of 52.95 as
100th centile, we transformed all WCXR scores into centile
scores, and then calculated the 26.08th centile for the Brittany
region and 21.75th centile for Wisconsin. The GEE model
(adjusted for repeated measures) has an overall data difference of
4.48 or 4–6 score points, which corresponds to an overall mean
difference of 13.81–11.52=2.29, which then corresponds to an
overall centile difference of 26.08–21.75=4.33.
4. Discussion
We believe that this international project is the first
longitudinal study comparing pulmonary outcomes from CF
patients diagnosed early through NBS in two different regionsof two different countries. Unexpectedly, the results of our
study clearly show that Wisconsin CF patients identified
through newborn screening have a milder course of pulmonary
disease than Brittany CF patients identified through newborn
screening. Longitudinal chest X-rays scored with the WCXR
scoring system demonstrate worse pulmonary disease among
Brittany patients that develops within the first 6 years of life.
The major subcomponent of the WCXR scoring system that
determines this difference is bronchiectasis, as Brittany patients
have a higher rate of development of bronchiectasis in their first
6 years of life than Wisconsin patients. Since bronchiectasis is
an irreversible structural lung disease caused by persistent,
severe infections [24], this is likely due to a higher rate of early
infections among Brittany patients. Supporting our finding of
milder pulmonary disease in Wisconsin patients compared to
Brittany patients using WCXR scores are the results of percent
predicted FEV1, which are better in Wisconsin patients, and
lower odds of hospitalization in Wisconsin patients. One
critique of the hospitalization results is likely baseline
differential hospitalization rates in France, where the national
health care system allows physicians to hospitalize patients
without concern for medical costs covered by patients' families,
compared to the United States, where physicians may be more
hesitant because of such medical costs. However, it is
interesting to note that the improved condition of the Wisconsin
patients is not attributable to increased hospitalizations. On the
other hand, the confounding effect of hospitalization in the GEE
model suggests that paradoxically such exposures associated
with CF centre care may be detrimental.
Although we have clearly discovered milder pulmonary
disease in Wisconsin compared to Brittany CF patients, we do
not have an explanation for this difference from our current data
but only hypotheses that can be studied in the future. Although
we assumed that genotype could have been a potential reason
for the difference, as suggested in several studies [24–26], our
sample size was limiting. Early nutritional deficiencies as
shown by significantly subnormal weights or heights could
have been another potential reason [27]. Our GEE model
incorporating the child's weight with region and revealing a
confounding effect supports this potential explanatory variable.
However, the average weight and height of the patients at ages
6 and 10 were near the 50th country-specific percentile in both
populations. Nevertheless, it is interesting to note that female
Brittany patients have a lower average country-specific
percentile for both weight and height than their Wisconsin
counterparts, as well as the male Brittany patients.
Another hypothesis that may account for the difference is
that environmental exposures leading to either increased
infections or increased severity of infections with Pseudomo-
nas aeruginosa and Staphylococcus aureus differ between the
two populations. Unfortunately, the respiratory culture data
available in this study were not comparable between the two
populations, so we cannot state definitively that Brittany
patients have more respiratory infections with these pathogens
than Wisconsin patients. Several studies have shown that cross-
infections can occur with social interactions and while at
specialized CF centres [28–30]. Although it is difficult, if not
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may lead to cross-infection between CF patients retrospectively,
all types of such social interactions are strongly discouraged
at Wisconsin CF centres. On the other hand, at Brittany CF
centres, patients are given guidelines to protect themselves
when interacting with other CF patients but do not receive
similar discouragement. In addition, they had more hospitaliza-
tions and perhaps potential for cross-infection. In connection
with this issue, Bush [31] has recently emphasized the hazards
of CF centre care in the context of newborn screening and the
concept of “first, do no harm.”
Thus, this study definitively demonstrated milder pulmonary
disease among Wisconsin CF patients identified through NBS
compared to a similar group of Brittany CF patients, but more
research is needed to elucidate the cause of the findings.
Moreover, since it is a retrospective study, it is unknown
whether similar disparities and conditions exist today.
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